Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

Now Viewing

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Rationale for Ultra-Low PSA Threshold Analysis

Key Themes:

• Post hoc analysis focusing on PSA response thresholds
• Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
• PSA as a surrogate biomarker in advanced prostate cancer

Expert Insights:

• Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.

The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.